{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:02:41Z","timestamp":1787652161038,"version":"build-2736575974"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["(AA\/18\/2\/34218"],"award-info":[{"award-number":["(AA\/18\/2\/34218"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/13\/43\/30324"],"award-info":[{"award-number":["FS\/13\/43\/30324"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["116074"],"award-info":[{"award-number":["116074"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["BigData@Heart"],"award-info":[{"award-number":["BigData@Heart"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001674","name":"Fondation Leducq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010447","name":"Deutsches Zentrum f\u00fcr Herz-Kreislaufforschung","doi-asserted-by":"publisher","award":["AFNET"],"award-info":[{"award-number":["AFNET"]}],"id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>Large-scale screening for atrial fibrillation (AF) requires reliable methods to identify at-risk populations. Using an experimental semi-quantitative biomarker assay, B-type natriuretic peptide (BNP) and fibroblast growth factor 23 (FGF23) were recently identified as the most suitable biomarkers for detecting AF in combination with simple morphometric parameters (age, sex, and body mass index [BMI]). In this study, we validated the AF model using standardised, high-throughput, high-sensitivity biomarker assays.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods and findings<\/jats:title><jats:p>For this study, 1,625 consecutive patients with either (1) diagnosed AF or (2) sinus rhythm with CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc score of 2 or more were recruited from a large teaching hospital in Birmingham, West Midlands, UK, between September 2014 and February 2018. Seven-day ambulatory ECG monitoring excluded silent AF. Patients with tachyarrhythmias apart from AF and incomplete cases were excluded. AF was diagnosed according to current clinical guidelines and confirmed by ECG. We developed a high-throughput, high-sensitivity assay for FGF23, quantified plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) and FGF23, and compared results to the previously used multibiomarker research assay. Data were fitted to the previously derived model, adjusting for differences in measurement platforms and known confounders (heart failure and chronic kidney disease). In 1,084 patients (46% with AF; median [Q1, Q3] age 70 [60, 78] years, median [Q1, Q3] BMI 28.8 [25.1, 32.8] kg\/m<jats:sup>2<\/jats:sup>, 59% males), patients with AF had higher concentrations of NT-proBNP (median [Q1, Q3] per 100 pg\/ml: with AF 12.00 [4.19, 30.15], without AF 4.25 [1.17, 15.70];<jats:italic>p &lt;<\/jats:italic>0.001) and FGF23 (median [Q1, Q3] per 100 pg\/ml: with AF 1.93 [1.30, 4.16], without AF 1.55 [1.04, 2.62];<jats:italic>p &lt;<\/jats:italic>0.001). Univariate associations remained after adjusting for heart failure and estimated glomerular filtration rate, known confounders of NT-proBNP and FGF23. The fitted model yielded a C-statistic of 0.688 (95% CI 0.656, 0.719), almost identical to that of the derived model (C-statistic 0.691; 95% CI 0.638, 0.744). The key limitation is that this validation was performed in a cohort that is very similar demographically to the one used in model development, calling for further external validation.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Conclusions<\/jats:title><jats:p>Age, sex, and BMI combined with elevated NT-proBNP and elevated FGF23, quantified on a high-throughput platform, reliably identify patients with AF.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Trial registration<\/jats:title><jats:p>Registry IRAS ID 97753 Health Research Authority (HRA), United Kingdom<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pmed.1003405","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T21:07:46Z","timestamp":1612386466000},"page":"e1003405","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6747-8813","authenticated-orcid":true,"given":"Winnie","family":"Chua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4900-9618","authenticated-orcid":true,"given":"Jonathan P.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor R.","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanish","family":"Purmah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgiana","family":"Neculau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6336-0327","authenticated-orcid":true,"given":"Muhammad","family":"Jawad-Ul-Qamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalisha","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5204-8554","authenticated-orcid":true,"given":"Ashley","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha P.","family":"Tull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frantisek","family":"Nehaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8744-7152","authenticated-orcid":true,"given":"Peter","family":"Kastner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2061-091X","authenticated-orcid":true,"given":"Georgios V.","family":"Gkoutos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3171-3551","authenticated-orcid":true,"given":"Davor","family":"Pavlovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0577-7081","authenticated-orcid":true,"given":"Charles J.","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-0197","authenticated-orcid":true,"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-1733","authenticated-orcid":true,"given":"Larissa","family":"Fabritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"key":"pmed.1003405.ref001","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ahj.2019.06.011","article-title":"Design and rationale of a pragmatic trial integrating routine screening for atrial fibrillation at primary care visits: the VITAL-AF trial","volume":"215","author":"JM Ashburner","year":"2019","journal-title":"Am Heart J"},{"issue":"9989","key":"pmed.1003405.ref002","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study","volume":"386","author":"RB Schnabel","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"pmed.1003405.ref003","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.108.825380","article-title":"Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop","volume":"119","author":"EJ Benjamin","year":"2009","journal-title":"Circulation"},{"issue":"19","key":"pmed.1003405.ref004","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1161\/CIRCULATIONAHA.116.026693","article-title":"Screening for atrial fibrillation: a report of the AF-SCREEN International Collaboration","volume":"135","author":"B Freedman","year":"2017","journal-title":"Circulation"},{"key":"pmed.1003405.ref005","doi-asserted-by":"crossref","unstructured":"Fabritz L, Crijns H, Guasch E, Goette A, Haeusler KG, Kotecha D, et al. Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET\/EHRA Consensus Conference. Europace. 2021 Jan 12. doi: 10.1093\/europace\/euaa279","DOI":"10.1093\/europace\/euaa279"},{"issue":"16","key":"pmed.1003405.ref006","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1093\/eurheartj\/ehy815","article-title":"Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation","volume":"40","author":"W Chua","year":"2019","journal-title":"Eur Heart J"},{"issue":"4","key":"pmed.1003405.ref007","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nrcardio.2015.194","article-title":"Expert consensus document: defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment","volume":"13","author":"L Fabritz","year":"2016","journal-title":"Nat Rev Cardiol"},{"issue":"27","key":"pmed.1003405.ref008","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"P Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"issue":"2","key":"pmed.1003405.ref009","doi-asserted-by":"crossref","first-page":"e000102","DOI":"10.1161\/JAHA.112.000102","article-title":"Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium","volume":"2","author":"A Alonso","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"pmed.1003405.ref010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ahj.2016.05.004","article-title":"A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study","volume":"178","author":"IE Christophersen","year":"2016","journal-title":"Am Heart J"},{"issue":"38","key":"pmed.1003405.ref011","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"P Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"issue":"9","key":"pmed.1003405.ref012","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"AS Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"4","key":"pmed.1003405.ref013","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","article-title":"Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values","volume":"53","author":"AS Levey","year":"2007","journal-title":"Clin Chem"},{"issue":"1","key":"pmed.1003405.ref014","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"DW Cockcroft","year":"1976","journal-title":"Nephron"},{"issue":"11","key":"pmed.1003405.ref015","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.jacc.2018.01.021","article-title":"N-terminal pro-B-type natriuretic peptide in the emergency department: the ICON-RELOADED Study","volume":"71","author":"JL Januzzi","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"pmed.1003405.ref016","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jamacardio.2017.3180","article-title":"Incidence of previously undiagnosed atrial fibrillation using insertable cardiac monitors in a high-risk population: the REVEAL AF Study","volume":"2","author":"JA Reiffel","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"25","key":"pmed.1003405.ref017","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jacc.2007.09.021","article-title":"Natriuretic peptides","volume":"50","author":"LB Daniels","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"pmed.1003405.ref018","first-page":"e1054","article-title":"Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association","volume":"135","author":"SL Chow","year":"2017","journal-title":"Circulation"},{"issue":"18","key":"pmed.1003405.ref019","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/CIRCULATIONAHA.109.873265","article-title":"N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study","volume":"120","author":"KK Patton","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"pmed.1003405.ref020","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/europace\/euw319","article-title":"Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide: the STROKESTOP II study design","volume":"19","author":"J Engdahl","year":"2017","journal-title":"Europace"},{"issue":"10035","key":"pmed.1003405.ref021","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study","volume":"387","author":"Z Hijazi","year":"2016","journal-title":"Lancet"},{"issue":"22","key":"pmed.1003405.ref022","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1161\/CIRCULATIONAHA.116.022802","article-title":"Performance and validation of a novel biomarker-based stroke risk score for atrial fibrillation","volume":"134","author":"J Oldgren","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"pmed.1003405.ref023","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jchf.2013.02.004","article-title":"Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure)","volume":"1","author":"M Richards","year":"2013","journal-title":"JACC Heart Fail"},{"issue":"46","key":"pmed.1003405.ref024","first-page":"3250","article-title":"Atrial fibrillation in heart failure: what should we do?","volume":"36","author":"D Kotecha","year":"2015","journal-title":"Eur Heart J"},{"issue":"12","key":"pmed.1003405.ref025","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"T Isakova","year":"2011","journal-title":"Kidney Int"},{"issue":"3","key":"pmed.1003405.ref026","doi-asserted-by":"crossref","first-page":"e000936","DOI":"10.1161\/JAHA.114.000936","article-title":"Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study","volume":"3","author":"PL Lutsey","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"pmed.1003405.ref027","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jacc.2012.03.040","article-title":"Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study).","volume":"60","author":"JH Ix","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"pmed.1003405.ref028","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"C Faul","year":"2011","journal-title":"J Clin Invest"},{"issue":"1","key":"pmed.1003405.ref029","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1038\/s41598-017-02068-6","article-title":"FGF23\/FGFR4-mediated left ventricular hypertrophy is reversible","volume":"7","author":"A Grabner","year":"2017","journal-title":"Sci Rep"},{"issue":"21","key":"pmed.1003405.ref030","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1093\/eurheartj\/ehr215","article-title":"The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation","volume":"32","author":"S Seiler","year":"2011","journal-title":"Eur Heart J"},{"issue":"4","key":"pmed.1003405.ref031","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.113.005499","article-title":"Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS).","volume":"130","author":"JS Mathew","year":"2014","journal-title":"Circulation"},{"issue":"5","key":"pmed.1003405.ref032","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jamacardio.2016.1445","article-title":"Association of fibroblast growth factor 23 with atrial fibrillation in chronic kidney disease, from the Chronic Renal Insufficiency Cohort Study","volume":"1","author":"R Mehta","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"6","key":"pmed.1003405.ref033","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.cmet.2015.09.002","article-title":"Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy","volume":"22","author":"A Grabner","year":"2015","journal-title":"Cell Metab"},{"key":"pmed.1003405.ref034","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cyto.2018.08.005","article-title":"Lower soluble Klotho and higher fibroblast growth factor 23 serum levels are associated with episodes of atrial fibrillation","volume":"111","author":"K Mizia-Stec","year":"2018","journal-title":"Cytokine"},{"issue":"7","key":"pmed.1003405.ref035","doi-asserted-by":"crossref","first-page":"e016041","DOI":"10.1161\/JAHA.120.016041","article-title":"Clinical potential of targeting fibroblast growth factor-23 and alphaKlotho in the treatment of uremic cardiomyopathy","volume":"9","author":"JP Law","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"pmed.1003405.ref036","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jacep.2016.12.015","article-title":"Cost-effectiveness and clinical effectiveness of the risk factor management clinic in atrial fibrillation: the CENT Study","volume":"3","author":"RK Pathak","year":"2017","journal-title":"JACC Clin Electrophysiol"},{"issue":"3","key":"pmed.1003405.ref037","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/europace\/eux318","article-title":"Integrating new approaches to atrial fibrillation management: the 6th AFNET\/EHRA Consensus Conference","volume":"20","author":"D Kotecha","year":"2018","journal-title":"Europace"},{"issue":"4","key":"pmed.1003405.ref038","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.4022\/jafib.2058","article-title":"The biomarkers NT-proBNP and CA-125 are elevated in patients with idiopathic atrial fibrillation","volume":"11","author":"EA Dudink","year":"2018","journal-title":"J Atr Fibrillation"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T16:49:49Z","timestamp":1671036589000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003405"}},"subtitle":[],"editor":[{"given":"Patrick","family":"Sulzgruber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003405","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,3]]}}}